Unintended Immunological Consequences of Biologic Therapy by Henrickson, Sarah E. et al.
Unintended Immunological Consequences of Biologic Therapy
Sarah E. Henrickson, MD, PhD1,†, Melanie A. Ruffner, MD, PhD1,†, and Mildred Kwan, MD, 
PhD2,*
1The Children’s Hospital of Philadelphia, Division of Allergy and Immunology, 3550 Market St. 3rd 
floor, Philadelphia, PA 19104
2University of North Carolina School of Medicine, Department of Internal Medicine, Division of 
Rheumatology, Allergy & Immunology, 3300 Thurston, CB #7280, Chapel, Hill, NC
Abstract
Recent advances in the understanding of immune dysregulation in autoimmune diseases have 
enabled the development of new monoclonal antibody based drugs called biologics. Biologics 
have been used to target aberrant immune responses in many diseases, but patients with 
rheumatologic and other autoimmune diseases have benefited the most and improvements in 
outcomes have been significant. The use of biologics is not without hazard; however, as these 
agents block immune pathways adapted to protect the host. This has been borne out by increased 
rates of infections as well as induction of new autoimmune and hematologic adverse effects. As 
new drugs for the treatment of autoimmune conditions are entering the pipeline, it is incumbent on 
the practicing immunologist to understand the mechanism of these biologics and the implications 
of clinical use.
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Introduction
Our understanding of immune function has made great progress over the last few decades. 
This progress has led to the development of monoclonal antibodies (mAbs, biologics) that 
have revolutionized the treatment of rheumatologic/autoimmune diseases [1]. Small 
molecules inhibitors such as the Janus kinase (JAK) inhibitors are also important drugs in 
treatment of autoimmune disease, but will not be addressed in this review. Biologics provide 
therapy that target specific aspects of the immune system in order to combat autoimmune 
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responses. Now there are effective therapies for chronic systemic inflammatory conditions 
that previously had high rates of morbidity and mortality. Although biologics are 
tremendously successful in treating chronic inflammatory diseases, there are significant risks 
as specific components of immunological function are suppressed by these drugs [2]. As 
some of these biologics may mimic known immunodeficiencies, this is an important topic 
for immunologists to understand. In this review, we present currently available therapies for 
autoimmune/inflammatory conditions (Table 1), the immune mechanisms that they target 
and known and possible adverse outcomes based on their targets.
Innate Immunity
Complement
The complement system targets pathogens using three key mechanisms: bacterial cytolysis, 
pathogen opsonization allowing targeting by phagocytes, and stimulating inflammation via 
release of anaphylatoxins. The importance of the complement system is emphasized by 
known deficiencies in complement components such as C5 which results in invasive 
Neisseria infections [3]. Recent data also indicates that complement is involved in other 
pathways and is key in immune downregulation and homeostasis. Indeed, derangements in 
complement activation (e.g. atypical hemolytic uremic syndrome (aHUS)) or regulation (e.g. 
paroxysmal nocturnal hemoglobinuria (PNH)) may lead to inflammatory disease [4].
Eculizumab is currently the only biologic targeting the complement pathway that is 
approved and is indicated for treatment of PNH [5, 6] and aHUS [5] Eculizumab is a 
humanized anti-C5 mAb that selectively blocks activation of C5, release of C5a, and 
initiation of the membrane attack complex [5, 6]. PNH is a rare disorder resulting from an 
acquired somatic mutation in phosphatidylinositol glycan class A (PIGA) gene in 
hematopoietic stem cells leading to loss of glycophosphatidylinositol (GPI) anchor synthesis 
and expression of GPI anchored proteins such as decay accelerating factor (DAF or CD55) 
and CD59, which are key in prevention of complement activation on host cells. PNH 
patients suffer from hemolytic anemia, thrombosis, and cytopenias at significant morbidity 
and mortality with limited options for treatment until the advent of eculizumab. Eculizumab 
was approved for PNH in 2 small randomized clinical trials that showed significant 
improvement in outcomes for hemolysis and thrombosis. However, a significant subset of 
patients were refractory to treatment likely due to C3b deposition on red cells causing 
clearance in the spleen. Based on this observation, drugs targeting C3 are currently in the 
pipeline for the treatment of PNH [5, 6].
As eculizumab blocks C5, there have been concerns about susceptibility to invasive 
meningococcal infection. Patients were given meningococcal vaccine during clinical trials, 
but 2 patients developed meningococcal serotype B infections that resolved with antibiotic 
therapy. As there have been cases of serotype B infections on eculizumab, it is now 
recommended that patients receive meningococcal vaccination and prophylactic antibiotics 
[3, 5]. With the introduction of Bexsero, a meningococcal serotype B vaccine, consideration 
for use of this vaccine with eculizumab treatment is likely. As the clinical trials and the post 
marketing data are sparse, the use of this drug should be done with the utmost of caution due 
to susceptibility to N. meningitides. Additionally, caution will be needed as therapeutics 
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targeting C3 are in development, and C3 deficiency engenders a broader range of 
susceptibility to infectious pyogenic bacteria such as pneumococcus.
Cytokines
TNF-α, IL-1, and IL-6 are innate pro-inflammatory cytokines that are induced by infection. 
TNF-α is the primary cytokine that induces the inflammatory cascade as it is able to induce 
both IL-1 and IL-6. IL-1 is also able to induce IL-6 directly. In concert, this cascade 
promotes leukocyte recruitment, the activation of T cells, and the elaboration of other pro-
inflammatory molecules such as serum amyloid A and C-reactive protein [7]. These 
cytokines have crucial disease inducing roles in autoimmune diseases (e.g. rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD)) and autoinflammatory diseases (e.g. 
cryopyrin associated periodic syndromes (CAPS)) and are thus important therapeutic targets 
[8].
TNF-α is induced by microbial products during the initiation of an infection and in turn 
initiates the inflammatory cascade. This makes TNF an important druggable target, but as it 
is at the apex of the pathway, blocking this cytokine also leaves patients susceptible to 
infection due to its broad effects in immunity. TNF inhibitors (TNFis) were the initial 
biologics that were approved for use in RA. Their immunological adverse effects are 
reviewed in detail in Her et al [1]. Suffice it to say that this class of drugs has a high rate of 
serious infections, including tuberculosis, that were not anticipated in the clinical trials and 
careful screening for Mtb worldwide and fungal infections (such as Histoplasma) is critical 
in endemic regions Autoimmune conditions and paradoxical inflammation have also been 
induced by TNFis, which necessitates discontinuation of treatment [1].
IL-1
IL-1 is a prototypic pro-inflammatory cytokine that shares many properties with TNF-α and 
consists of 2 forms, IL-1α and IL-1β, the main biologically active form being IL-1β. 
Secretion of IL-1β is tightly regulated and released upon inflammasome activation in 
monocyte/macrophages during infection and inflammation. IL-1 serves to enhance the 
effector functions of innate immune cells and also facilitates the action of B cells and CD4+ 
Th cells [9]. As IL-1 is a key inflammatory cytokine driving innate and adaptive responses, it 
is an important contributor to autoimmune (e.g. RA) [9] and autoinflammatory (e.g. CAPS)
[8]conditions leading to chronic systemic inflammation and symptomatology. Due to the 
critical role of IL-1 in inflammatory diseases, the application of IL-1 blockade for 
therapeutic treatment has become an important aspect of biologic development for a 
multitude of conditions with anakinra, canakinumab, and rilonacept currently approved [9, 
10, 8].
Although IL-1 is important in induction of inflammatory responses to pathogens, the use of 
IL-1 antagonists has been quite safe with mainly increases in common bacterial and viral 
infections. Unlike other classes of biologics, such as TNFis, there is no increase in 
opportunistic infections with the use of anakinra such as M. tuberculosis (Mtb) reactivation 
[8] although with longer acting canakinumab (anti-IL-1β) there was a somewhat higher rate 
of infections (e.g. nasopharyngitis, urinary tract infection) [10][11]. Indeed, use of anakinra 
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in patients with inflammatory disease during active infections (e.g. hidradenitis suppurativa) 
or with treatment of autoimmune manifestations in immunodeficient patients (i.e. IBD in 
chronic granulomatous disease) controls inflammation without causing exacerbation or onset 
of infection. There are reported cases of neutropenia IL-1 blockade, but there have only been 
rare cases of neutrophil counts less than 500 cells/mL (all without significant infections) and 
neutropenia corrects with cessation of therapy [8].
IL-6
IL-6 is a pleiotropic cytokine induced by TNF-α and IL-1 and functions in T cell expansion 
and activation, B cell differentiation, and activation of acute phase responses. This cytokine 
affects immune function and metabolic pathways including lipid metabolism, 
vasculopathies, and endocrine disease. Although downstream from TNF-α and IL-1, IL-6 is 
critical to immunity as proven by individuals with Hyper IgE syndrome (HIES) who 
demonstrate decreased IL-6 and IL-17 activity allowing recurrent infections particularly 
with Gram-negative bacteria and fungi. Although uncommon, children who develop 
inhibitory IL-6 autoantibodies are susceptible to cutaneous staphylococcal infections [12]. 
Although IL-6 was thought to be a biomarker of inflammatory disease, it is clear that IL-6 is 
involved in disease induction in autoimmune disease (e.g. RA, IBD)[13]. Tocilizumab is an 
IL-6 receptor (IL-6R) blocking humanized mAb approved for treatment of RA [13] and 
polyarticular and systemic juvenile idiopathic arthritis (PJIA and SJIA)[13, 14]. 
Tocilizumab, as well as other IL-6R and IL-6 inhibiting biologics, are currently in clinical 
trials to treat other autoimmune/inflammatory conditions including systemic sclerosis and 
adult Still’s disease [14].
Blocking IL-6 therapeutically is difficult as this cytokine is crucial in multiple immune 
pathways including Th17 induction and acute phase responses [14, 12]. As such, it would be 
predicted that biologics targeting this cytokine would increase infections and impact other 
aspects of immune function. In clinical trials, tocilizumab has had an increased rate of 
infections with respiratory tract infections being most common, but increased cutaneous 
infections were also noted [15, 16]. Mtb reactivation has also been reported although at a 
lower rate than with TNFis and screening for tuberculosis is recommended [1, 16]. Other 
adverse immune effects observed with tocilizumab include some cases of neutropenia that 
were not associated with serious infections [10, 17, 16] Finally, in trials for SJIA, there were 
reports of episodes of macrophage activation syndrome (MAS) upon withdrawal of drug, 
although SJIA patients have an overall increased rate of MAS [17]. There are a significant 
number of biologics targeting IL-6 currently in trials (Table 2) and based on the mechanism 
of action of this cytokine, other possible immunological derangements include a spectrum of 
infections similar to deficiencies that result in Th17 defects as each biologic will likely have 
differing off target effects.
Adaptive Immunity
IL-17
IL-17A is an IL-17 family member and has proinflammatory functions linked to secretion of 
TNF, IL-6, IL-1 and GM-CSF. IL-17A is fundamental to eradication of extracellular bacteria 
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and fungal infections, but is also associated with autoimmune diseases including RA, 
psoriasis and multiple sclerosis (MS)[18]. Therefore, while IL-17 blockade could improve 
immune dysregulation in selected autoimmune conditions , it potentially increases fungal 
and extracellular bacterial infection. In humans, IL-17 pathway deficiencies lead to chronic 
mucocutaneous candidiasis [19]. Additionally, Th17 cells are important in combating 
mycobacterial infections making Mtb reactivation a concern [20]. Secukinumab, an anti-
IL-17A mAb, is approved for plaque psoriasis [21–24], ankylosing spondylitis (AS) [25] and 
psoriatic arthritis (PsA)[26, 27]. Studies and trials have demonstrated an overall increase in 
infections with secukinumab versus placebo, including the expected increase in candida 
infections (mostly mild to moderate oral or genital infections whose incidence was dose 
dependent)[23, 28, 27] [29] oral herpes infections [30], as well as tinea pedia and two cases 
of perianal dermatophytosis [28]. In addition, neutropenia , and Crohn’s disease (CD) were 
noted to be increased versus placebo in some studies[21, 22, 24–26]. There was no Mtb 
reactivation or invasive fungal infections noted [30], but it is recommended to screen for TB 
prior to initiating therapy and to use caution if considering use in a patient with active CD
IL-12/IL-23
IL-23 is a member of the IL-12 family, which also includes IL-27 and IL-35. This complex 
family of heterodimeric cytokines share cytokine subunits, but have divergent, sometimes 
orthogonal, functions. For example, although IL-12 and IL-23 share IL-12p40, IL-12 
induces Th1 differentiation while IL-23 plays a role in Th17 differentiation/maintenance 
[31]. As discussed previously, immunodeficiency patients with Th17 pathway mutations 
have susceptibility to mucocutaneous candidiasis, mycobacteria, salmonella and S. aureus 
induced cold abscesses, but these infections were not seen in ustekinumab trials [18]. Given 
that this cytokine subunit is shared with IL-12, it is important to consider that effect as well. 
Mendelian susceptibility to mycobacterial disease (MSMD) is a broad set of diseases (such 
as IL12B, IL12RB1 mutations), which impact production and response to IFN-γ and are 
characterized by susceptibility to infections including Mycobacteria (i.e. BCG vaccine 
strains, MTb, etc), as well as Candida and Salmonella, among others [32]. IL-12Rβ1 defects 
are the most common cause of MSMD, with multiple mutations and broad clinical 
phenotype with susceptibility to mycobacteria (non BCG), invasive salmonellosis, and 
Candida, in addition to less frequent infections with bacteria (Klebsiella, S. pneumoniae, 
Nocardia) and other fungi [32]. Patients with IL-12p40 deficiency lack IL-12 and IL-23, and 
are characterized by BCG-osis after vaccination, salmonellosis and infections similar to 
IL-12Rβ1 deficiency [32]. Ustekinumab is a human IgG1 anti-IL-12p40 mAb. It is approved 
for treatment of severe plaque psoriasis and PsA [33–35]. There was no mention of systemic 
candidal infections in trials [36, 37] although there were higher rates of infection more 
broadly, most commonly including upper respiratory tract infections/nasopharyngitis [38, 
39], but also reported a case of asymptomatic Mtb reactivation [38, 40], herpes zoster [34, 
37] and cellulitis [39, 34]. It is recommended to screen for TB prior to initiating therapy and 
not to treat patients with active TB and to treat latent TB in patients prior to initiating 
therapy. Malignancy was also reported with non-melanoma skin cancer being most common 
[37]. Finally, one case of reversible posterior leukencephalopathy syndrome was reported
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IL-2Rα (CD25)
IL-2Rα, one chain of the high affinity IL-2 receptor (IL-2R), is found on activated T cells 
and regulatory T (Treg) cells. Daclizumab, blocks the IL-2 binding site on IL-2R, has been 
approved for treatment of organ transplant rejection, and in a phase III trial of daclizumab 
showed superiority in relapsing remitting MS versus IFN β-1-α[41]. With regards to adverse 
events, when daclizumab was compared to IFN β-1-a for relapsing-remitting MS, there was 
a similar rate of herpes infection, upper respiratory tract infections and urinary tract 
infections and no episodes of PML [41]. If note, one study reported higher rates of 
aspergillus colonization in lung transplantation [42]. There were higher rates of elevated 
liver function tests and cutaneous reactions in the daclizumab group. In prior studies, higher 
infection rates, including cellulitis and wound infections, cutaneous reactions and LFT 
elevations were also noted [43, 44].
Basiliximab, a chimeric monoclonal antibody IL-2Rα antagonist, is approved for use in 
induction of tolerance and transplant rejection in kidney transplant and did not have a clear 
pattern of increased infection. In trials, there was concern with regards to possible increase 
in infections [45–49]. It carries a black box warning with regards to being administered by 
physicians familiar with immunosuppression and transplant.
T cell
CTLA-4
T cells require two signals for activation, TCR activation via cognate peptide-MHC complex 
and costimulation [50]. The prototypic costimulatory signal is transduced by CD28 on T 
cells binding to CD80/86 on antigen presenting cells. As T cell activation progresses, 
CTLA-4 is upregulated and transduces negative signals as it binds with higher affinity to 
CD80/86 blocking further interaction with CD28. CTLA-4 is also constitutively expressed 
on regulatory T cells and acts to preserve peripheral tolerance.
Abatacept, a fusion of the extracellular domain of CTLA-4 to an altered Fc segment of 
IgG1, was developed to block T cell costimulation by binding to CD80 and CD86, thus 
preventing T cell activation. It has been approved for RA and JIA [51–62]. By preventing 
proper activation of T cells, concern for opportunistic infection is appropriate. Prior to 
initiating abatacept, screening for latent TB is recommended and treatment for latent TB 
should be completed prior to abatacept initiation. In addition, screening for hepatitis 
infection is also recommendation given concern for reactivation. Common infections 
included upper respiratory tract infections, [54, 55, 58–60, 62, 63], nasopharyngitis [63, 52, 
54, 58, 59, 62], bronchitis [55, 62], UTI [63, 52, 60, 62] and sinusitis [56]. A small increase 
in herpes simplex was noted versus placebo [53], as well as influenza and gastroenteritis 
[64]. Serious infections included pneumonia [63, 52, 55, 58, 59, 62], bronchitis [55], 
cellulitis [65, 60] and urinary tract infections [63, 62, 52], pyelonephritis and diverticulitis. 
Infections with Candida [53, 66], TB [53][67],noted to be in patients from endemic areas, 
herpes zoster [66] , ABPA[53], histoplasmosis [66], malignancies, which were generally 
consistent with placebo other than increases in lymphoma and lung malignancy which were 
argued to be consistent with the RA population [53, 52, 51], and autoimmunity (generally 
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psoriasis, with a few episodes of development of ANA or anti-dsDNA antibodies[64]) were 
also reported [63, 66, 55] though some of the studies were not placebo controlled.Overall, 
meta-analyses of abatacept studies demonstrated no significant increase in serious [68] or 
overall infections [53, 51]. Of note, abatacept in combination with TNF antagonists was 
shown to increase infections without increasing efficacy and is not recommended. 
Interestingly, patients with LRBA deficiency (CTLA-4 deficiency based on defective 
CTLA-4 recycling) have shown improvement with abatacept administration, and has been 
shown recently to be effective in CTLA-4 haploinsufficient patients [69][70].
Belatacept, CTLA-4Ig with higher avidity, has been approved for kidney transplant rejection 
in EBV seropositive patients, given the black box concern for development of PTLD, with a 
higher risk in the EBV seronegative population, as well as in CMV seronegative patients or 
those who have received T cell therapies [71–73]. Adverse reactions included 
nasopharyngitis and serious infections including increased CMV [71]. There was increased 
malignancy (especially non-melanoma skin cancer) and fungal and viral infections at similar 
rates compared with use of cyclosporine alone [74, 73]. There was an increase in TB 
infections with belatacept versus cyclosporine, which was noted to generally be in endemic 
regions, and they recommend screening for and treating latent TB prior to initation[73]. 
Post-transplant lymphoproliferative disorder was also reported [72], more often in the CNS 
[73], and is a black box warning for this therapy [75]. Of note, PML has also been reported 
[73] as well as polyoma virus nephropathy (often with BK virus). They recommend 
prophylaxis for CMV and PCP for three months after transplant. Patients who are 
undergoing liver transplant are not recommended to receive belatacept given worse 
outcomes.
In the setting of cancer, much like chronic infection, adaptive immunity can become 
hampered in its ability to combat a chronic antigen. Specifically, T cells become exhausted 
[76], with inhibitory signals outweighing the effect of activating signals. In this setting, 
therapeutic activation is desired. When predicting possible adverse events, CTLA-4 knock 
out mice were noted to have rampant autoimmunity and eventual fatality [77]. In humans, 
CTLA-4 haploinsufficiency mutations yield a clinical phenotype consistent with common 
variable immune deficiency in addition to dysfunctional Tregs and autoimmunity [78]. 
Ipilimumab is a mAb that prevents CTLA-4 interaction with CD80/86 allowing reactivation 
of exhausted T cells by halting inhibitory signals [76]. Ipilimumab is approved for the 
treatment of metastatic melanoma and is in trials for non-small cell and small cell lung 
carcinoma, renal cell carcinoma, and prostate cancer [79–81]. Ipilimumab carries a black 
box warning for immune related adverse events (irAE), which include skin rash, 
inflammatory colitis, hypophysitis, elevated LFTs and other inflammatory conditions [82, 
79, 83]. Interestingly, treatment guidelines for many irAEs have been developed with good 
acute improvement, though some serious irAEs require cessation of therapy and high dose 
corticosteroids, and other therapies depending on the severity and affected organ [84, 82].
Adhesion Molecules
Leukocyte trafficking from the vasculature into the peripheral tissues involves three critical 
steps: rolling, firm adhesion and transendothelial migration. Selectins mediate initial 
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tethering and subsequent rolling of leukocytes along the endothelium [85, 86]. Leukocyte 
rolling permits further cell-cell interactions between integrins and endothelial adressins 
required for firm adhesion [85, 86]. Integrins are composed of α and β subunits that initiate 
intracellular signaling activating leukocytes when bound to their cognate addressin[85, 86], 
ultimately allowing for transendothelial migration. Genetic defects in cell adhesion have 
been identified resulting in Leukocyte Adhesion Deficiency (LAD) syndromes [85]. Starting 
in childhood, LAD patients have significant defects in antibacterial and antifungal defense 
resulting in characteristic non-purulent infections (oomphalitis and periodontitis) as well as 
invasive infections of other sites [85].
Natalizumab is a recombinant humanized IgG4 mAb that targets α4 integrin blocking the 
binding of both gut-specific α4β7 as well as α4β1 integrin (binds VCAM-1 on the blood 
brain barrier)[87]. Natalizumab is currently approved as monotherapy for relapsing forms of 
MS and as a second line agent for refractory IBD. A surprising outcome of natalizumab 
post-market surveillance was occurrence of progressive multifocal leukoencephalopathy 
(PML), a severe demyelinating disease associated with activation of latent JC virus infection 
in immunocompromised hosts [88, 89]. Efalizumab, a recombinant humanized neutralizing 
antibody to αLβ2 (LFA-1) had been approved for the treatment of severe psoriasis, but was 
withdrawn from the market in 2009 due to occurrence of three fatal cases of PML[90]. It is 
thought that due to impaired trafficking of lymphocytes into the CNS, there is a loss of 
lymphocyte-mediated CNS immunosurveillance which leads to the development of PML. 
Although not as well-known, there have been reports of increased rates of varicella zoster 
and herpes simplex central nervous system opportunistic infections in patients on 
natalizumab [91].
Lymphocytes bearing α4β7 integrin home to the gut where they bind mucosal adressin cell-
adhesion molecule-1 (MadCAM-1) expressed specifically on gut-associated lymphoid 
tissues (GALT). Vedolizumab, a recombinant humanized IgG1 antibody, is selective for gut 
tissue and binds only the α4β7 complex [86, 89]. Due to this selectivity, vedolizumab has a 
more limited infectious risk profile. No known cases of PML have been associated with 
vedolizumab. Not surprisingly, there were slight increases in gastroenteritis and enteric 
abscesses compared to placebo given that vedolizumab inhibits lymphocyte transmigration 
into the gut [89]. Although there are case reports raising concerns that decreased 
immunosurveillance of nasopharyngeal mucosa were causing systemic infections [89, 92], 
this was not statistically significant [89]. Vedolizumab is approved as second-line treatment 
of moderate to severe IBD TNFi non-responders.
B Cells
B cells have been implicated in numerous autoimmune conditions, particular those where 
prognosis or response to therapy can be associated with autoantibody status, e.g. systemic 
lupus erythematosus (SLE), or ANCA vasculitis. In addition to secreting harmful 
autoantibodies, B cells also release pro-inflammatory cytokines (lymphotoxin, TNFα and 
IL-6) and present antigen to autoreactive T cells [93–95]. Therefore, there has been 
considerable interest in development of B-cell targeted therapies for the treatment of 
autoimmune conditions.
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CD20 is a glycosylated phospholipid expressed on circulating B cells, but not B-cell 
hematopoietic precursors, plasmablasts or plasma cells [96]. Rituximab is a chimeric anti-
CD20 mAb which induces transient depletion of circulating peripheral B cells. Rituximab is 
approved for the treatment of refractory, indolent non-Hodgkins’ lymphoma, with 
methotrexate for TNFi-refractory RA, and for granulomatous polyangiitis. Of note, 
rituximab monotherapy in systemic lupus erythematosus (SLE) was not successful as many 
patients experienced worsening lupus flares with B cell reconstitution, which may in part be 
secondary to B-cell activation factor (BAFF) driven repopulation of autoreactive B cells 
following rituximab [97].
In initial clinical trials, transient hypogammaglobulinemia was seen in 14% of patients and 
average B cell recovery was 6-9 months following rituximab treatment [98, 99]. However, 
there have since been numerous reports of delayed reconstitution of memory B cells with 
hypogammaglobulinemia and recurrent infections in a subset of patients treated with 
rituximab [100–103]. Of note, several newer anti-CD20 mAbs have been developed, 
including ocrelizumab, ofatumumab, and veltuzumab. Ofatumumab was approved in a 
multi-drug regimen for treatment of chronic lymphocytic leukemia. Multiple clinical trials 
are ongoing with these biologics for both oncologic and rheumatologic conditions.
Depletion of B cells with anti-CD20 antibodies may also result in disruption of combined 
immune function. Both rituximab and oftatumumab bear black-box warnings regarding risk 
of PML and hepatitis B reactivation, deriving from post-market rituximab use. PML has 
been reported following rituximab use in malignancy as well as SLE, RA, and autoimmune 
cytopenias [104, 105]. Hepatitis B reactivation has mainly been seen with combined 
chemotherapy regimens for hematologic malignancy with fatalities reported [105]. 
Pneumocystis jiroveci infections have also been seen with combination regimens for 
malignancy and with rituximab monotherapy for autoimmune conditions, illustrating the 
importance of B cells in induction of specific T-cell immunity[105]. This is analogous to X-
linked agammaglobulinemia, or CD40-ligand deficiency, where defective B cell antigen 
presentation results in combined immunodeficiency. As only a small number of patients 
were affected by opportunistic infections following rituximab, there may be additional 
patient specific factors contributing to infectious adverse events.
As noted previously, it is thought that in some SLE patients BAFF drives rapid reconstitution 
of autoreactive B cells following rituximab monotherapy [97]. BAFF is a TNF-superfamily 
member secreted by multiple cell types (T follicular helper cells, monocytes, and dendritic 
cells) that is critical for maintaining B cell homeostasis [106–108, 97]. Elevated plasma 
BAFF levels have been correlated with increased disease activity in SLE and return of anti-
dsDNA antibodies following rituximab treatment [106, 97]. Belimumab, a human 
recombinant IgG targeting soluble BAFF only, is approved for the treatment of SLE. Data 
from trials demonstrated unchanged memory B cell populations, decreased naïve B cells, 
and decreased activated plasma cells. Retrospective analysis of a small cohort showed 
unchanged titers to tetanus, diphtheria, and pneumococcus, but perhaps decreased response 
to de novo antigen challenge (seasonal influenza vaccination)[109, 110]. Investigation into 
the immune consequences of BAFF inhibitor use in autoimmune disease is ongoing and 
include studies examining vaccine responses while on belimumab [111]. Long term follow 
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up data of SLE patients over four years of belimumab use (approximately half on 
concomitant steroid or mycophenolate) has been reassuring as rates of infection with 
belimumab were similar to those using systemic immunosuppressant alone (i.e. 
corticosteroids, antimalarial agents, azathioprine, mycophenolate mofetil, methotrexate, or 
leflunomide alone or in combination) [112]. Trials investigating combination therapy with 
rituximab followed by belimumab for prevention of B cell reconstitution in SLE and lupus 
nephritis are ongoing [97]. However, it remains unclear if combined anti-B cell therapy may 
create synergistic immunosuppressive effects such as prolonged hypogammaglobulinemia, 
increased incidence of PML, or other unexpected immunosuppression. Tabalumab and 
blisibimod (fusion peptide antagonist), two additional biologics that target soluble and 
membrane-bound BAFF, were examined in initial clinical trials for efficacy in SLE [108]. 
Despite initial positive data, further development of tabalumab was halted by its 
manufacturer due to perceived low therapeutic window compared to placebo. Blisibimod is 
currently in trials for SLE [113].
Atacicept is a human recombinant fusion protein containing the extracellular TACI receptor 
fused to IgG1 Fc and neutralizes BAFF and A PRoliferation Inducing Ligand (APRIL). 
APRIL is a TNF superfamily member of cytokines which acts in conjunction with BAFF by 
binding TACI, B-cell maturation antigen receptors on B cells to promote B cell development 
and proliferation [108]. Atacicept failed to meet 20% improvement criteria for RA, and in 
trials for MS, a paradoxical worsening of CNS lesions was seen [114]. During SLE trials, 
atacicept increased rates of opportunistic infection compared to placebo, including 
Haemophilus, Legionella, and Klebsiella [115]. Atacicept also significantly decreased IgG 
levels compared to placebo and this correlated with increased rates of invasive infections, 
some of which were fatal [115]. These factors led to discontinuation of trials for this 
biologic.
Conclusions
Biologics have vastly increased the number of effective treatments in autoimmune 
conditions. This has significantly improved treatment of patients with conditions that were 
previously difficult to treat or required corticosteroids which itself comes with numerous 
side effects. However, the success of these therapies must be tempered by the 
immunosuppressive effects of these agents. There can be predicted adverse outcomes as well 
as off target effects which have come to light with some biologics. As immunologists, we 
should be aware of these possible immunological safety issues with biologics as they 
continue to enter common use. This is particularly important as there is a dizzying array of 
biologics for not only autoimmune diseases (Table 2.), but also for oncologic and metabolic 
inflammatory diseases that are currently entering the therapeutic pipeline.
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Table 1
Currently Approved and Discontinued Biologics
Generic Name Brand Name Indications
Innate Immunity
Eculizumab Soliris Paroxysmal nocturnal hemoglobinuria
Anakinra Kineret Rheumatoid arthritis (RA)
Neonatal Onset Multisystem Inflammatory Disease
Canakinumab Ilaris Familial cold autoinflammatory syndrome
Muckle-Wells syndrome
Systemic juvenile idiopathic arthritis (SJIA)
Rilonacept Arcalyst Cryopyrin associated periodic syndromes
Tocilizumab Actemra RA, SJIA, Polyarticular juvenile idiopathic arthritis
Adaptive Immunity
Secukinumab Cosentyx Plaque psoriasis, Psoriatic arthritis
Ankylosing spondylitis
Ustekinumab Stelara Plaque psoriasis, Psoriatic arthritis
T cells
Basiliximab Simulect Renal transplant rejection
Abatacept Orencia RA, Juvenile idiopathic arthritis (JIA)
Belatacept Nulojix Renal transplant rejection
Ipilimumab Yervoy Melanoma, unresectable or metastatic; adjuvant
Adhesion Molecules
Natalizumab Tysabri Multiple sclerosis
Ankylosing spondylitis Crohn’s disease (CD)
Vedolizumab Entyvio Inflammatory bowel disease (CD, ulcerative colitis)
B cells
Rituximab Rituxan RA
Granulomatous polyangiitis, Microscopic polyangiitis
Belimumab Benlysta Systemic lupus erythematosus
Discontinued
Daclizumab Renal transplant rejection
Efalizumab Plaque psoriasis
Atacicept Systemic lupus erythematosus
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Table 2
Biologics in phase II/III trials
Generic Name Target Trial Indications
Gevokizumab IL-1β Diabetes, type II
Sifalimumab IFN-α Systemic lupus erythematosus
Rontalizumab IFN-α Systemic lupus erythematosus
Clazakizumab IL-6 Rheumatoid arthritis
Sirutumab IL-6 Rheumatoid arthritis
Depression
Mavrilimumab GM-CSFRα Rheumatoid arthritis
Ixekizumab IL-17 Plaque psoriasis
Brodalumab IL-17R Plaque psoriasis
Tildrakizumab IL-23 Plaque psoriasis
Guselkumab IL-23 p19 Plaque psoriasis
Oteliximab CD3ε Diabetes, type I
Teplizumab CD3 Diabetes, type I
Visilizumab CD3 Inflammatory bowel disease
Blisibimod BAFF Systemic lupus erythematosus
Tabalumab BAFF Systemic lupus erythematosus
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